Tau-PET imaging using [18F]flortaucipir (FTP) has recently been approved by the US Food and Drug Administration (FDA), and allows for the in-vivo visualization of aggregated tau. Alexis Moscoso Rial, PhD, University of Gothenburg, Gothenburg, Sweden, presents the prevalence and longitudinal clinical outcomes of [18F]FTP-positive individuals across the Alzheimer’s disease (AD) spectrum. In cognitively normal individuals, 8-9% were [18F]FTP positive, indicating that this imaging method aligns well with the onset of clinical symptoms and may be used to predict the onset of symptoms in those that are currently asymptomatic. Furthermore, 1 in 4 individuals who were Aβ-positive unimpaired were shown to also be tau-PET-positive. The overall prevalence in participants with mild cognitive impairment (MCI) and AD dementia was 38/1% and 71.2%, respectively. In all cohorts, tau-PET positivity was highly specific for Aβ pathology (≥95%). For individuals with mild cognitive impairment (MCI), those that were tau-positive had a very high risk (≥90%) of developing dementia within the next 10 years. The tau-PET-positive result can be categorized into moderate or advanced patterns, and current research aims to understand the clinical outcomes of each of these results. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть